CEO Tim Moore will share recent partnership and distribution news and a roadmap for the Company’s plans for the next quarter
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and cognitive function, is announcing that CEO Tim Moore will be presenting at the LD Micro Invitational XII, taking place June 7-9, 2022 at the Four Seasons Westlake Village in California, with more than 185 companies in attendance.
HAVN Life CEO Tim Moore will give a presentation on Tuesday, June 7 at 9:30am (Pacific), sharing updates on the Company’s growth and activities to an audience of investors and some of the most prominent companies in the small and micro-cap world. Mr. Moore will also host a Q & A session for investors following his presentation.
“I’m excited to be part of the 12th installment of the LD Micro gathering, and look forward to sharing our recent distribution and partnership successes, as well as upcoming plans with this illustrious group of investors and emerging companies,” says Moore. “It’s a great opportunity to connect with the investor community and share salient data on the market potential of the work we’re doing,” he adds.
WHO: Tim Moore, CEO of HAVN Life Sciences Inc.
WHEN: Tuesday, June 7, 2022 at 9:30am Pacific and 12:30pm Eastern
WHERE: The event is SOLD OUT but register HERE to attend virtually and watch the live stream
On Behalf of The Board of Directors
Chief Executive Officer
About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. What started out as a newsletter highlighting unique companies transformed into several virtual and in-person events hosted annually and positioned LD Micro as a leader in small- and micro-cap conferences. With the recent SRAX acquisition, LD gained access to the largest active base of micro-cap investors in the world at over five million and counting. For more information on LD Micro, visit ldmicro.com.
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding Mr. Moore’s attendance and presentation at the LD Micro event, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that Mr. Moore will not be able to attend and/or present at the LD Micro event as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release